logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Trastuzumab deruxtecan for HER2-positive metastatic or unresectable breast cancer

< Back

Trastuzumab deruxtecan for HER2-positive metastatic or unresectable breast cancer

Drugs

Cancer and Palliative Care

August 2019


Trastuzumab deruxtecan is in clinical development for the treatment of adults with HER2-positive, unresectable and/or metastatic breast cancer who have previously received anti-HER2 therapies. HER2-positive breast cancer is when the cancer tests positive for HER2 protein, which promotes the growth of cancer cells and tend to be more aggressive than other types of breast cancer. Metastatic breast cancer (stage IV) is when the cancer has spread beyond the breast and nearby lymph nodes to other organs in the body while unresectable means that the cancer cannot be treated by surgery. Treatment of the disease often involve the use of anti-HER2 therapies, chemotherapy or a combination of both.
Trastuzumab deruxtecan consists of an anti-HER2 therapy (trastuzumab) and a chemotherapy agent (deruxtecan) combined together as an antibody-drug conjugate. It has been developed such that the trastuzumab specifically binds to cancer cells that are HER2-positive which provides a targeted delivery of the cytotoxic deruxtecan inside cancer cells. This reduces systemic exposure to the chemotherapy with the potential to reduce associated toxicities and adverse effects. If licensed, trastuzumab deruxtecan will offer an additional treatment option for patients whose disease progressed despite previous treatment with other anti-HER2 therapies.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts